Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev. Soc. Bras. Med. Trop ; 53: e20190418, 2020. tab, graf
Article in English | LILACS | ID: biblio-1057263

ABSTRACT

Abstract INTRODUCTION: Pulmonary arterial hypertension (PAH) is a serious pulmonary circulation disease caused by several etiologies, including schistosomiasis. The present study retrospectively evaluated the clinical and hemodynamic characteristics of patients with schistosomal PAH (PAH-Sch) compared to those of non-Sch PAH patients (non-Sch PAH). METHODS: Patients treated at the Pronto-Socorro Cardiológico de Pernambuco and diagnosed by right cardiac catheterization were divided into PAH-Sch and non-Sch PAH groups. Their socio-demographic and clinical characteristics, N-terminal-pro B-type natriuretic peptide (NT-proBNP), and echocardiography and hemodynamic parameters were retrospectively reviewed. RESULTS: Among the included 98 patients (mean age, 45 ± 14 years; 68 women [69.4%]), we found 56 PAH-Sch and 42 non-Sch PAH. The age distribution was heterogeneous in the PAH-Sch group, with patients predominantly ranging from 50-59 (p <0.004). Dyspnea was the most common symptom, reported by 92 patients (93.8%), and commonly present for over two years prior to diagnosis. Clinical symptoms were similar in both groups, with no differences in functional class, pulmonary artery systolic pressure (p = 0.102), 6-minute walk test score (p = 0.234), NT-proBNP serum levels (p = 0.081), or hemodynamic parameters. CONCLUSIONS: Patients with PAH-Sch present clinical, laboratory, and hemodynamic profiles similar to those with PAH resulting from other etiologies of poor prognosis. PAH is an important manifestation of schistosomiasis in endemic regions that is often diagnosed late.


Subject(s)
Humans , Male , Female , Adult , Aged , Protein Precursors/blood , Schistosomiasis/complications , Atrial Natriuretic Factor/blood , Pulmonary Arterial Hypertension/etiology , Socioeconomic Factors , Echocardiography , Biomarkers/blood , Retrospective Studies , Pulmonary Arterial Hypertension/blood , Middle Aged
2.
Int. j. cardiovasc. sci. (Impr.) ; 32(3): 297-301, May-June 2019. graf
Article in English | LILACS | ID: biblio-1002228

ABSTRACT

Uterine leiomyoma and coronary artery disease are two common diseases in women. However, the association of uterine bleeding caused by leiomyoma with unstable coronary syndrome is not frequent. Here we describe a case of a patient with active vaginal bleeding and unstable angina who underwent a unique approach by performing percutaneous procedures. The report demonstrates that new interventional options can be used to control active bleeding in patients in need of coronary angioplasty


Subject(s)
Humans , Female , Adult , Uterine Hemorrhage/complications , Women , Stents , Angioplasty , Platelet Aggregation Inhibitors/therapeutic use , Angioplasty, Balloon, Coronary/methods , Embolization, Therapeutic/methods , Leiomyoma
3.
Arq. bras. cardiol ; 109(5): 440-447, Nov. 2017. tab, graf
Article in English | LILACS | ID: biblio-887971

ABSTRACT

Abstract Background: Left atrial appendage closure (LAAC) is an effective alternative to oral anticoagulation (OA) for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Objective: To present the immediate results and late outcomes of patients submitted to LAAC and included in the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. Methods: 91 patients with NVAF, high stroke risk (CHA2DS2VASc score = 4.5 ± 1.5) and restrictions to OAC (HAS-BLED score = 3.6 ± 1.0) underwent 92 LAAC procedures using either the Amplatzer cardiac plug or the Watchman device in 11 centers in Brazil, between late 2010 and mid 2016. Results: Ninety-six devices were used (1.04 device/procedure, including an additional non-dedicated device), with a procedural success rate of 97.8%. Associated procedures were performed in 8.7% of the patients. Complete LAAC was obtained in 93.3% of the successful cases. In cases of incomplete closure, no residual leak was larger than 2.5 mm. One patient needed simultaneous implantation of 2 devices. There were 7 periprocedural major (5 pericardial effusions requiring pericardiocentesis, 1 non-dedicated device embolization and 1 coronary air embolism without sequelae) and 4 minor complications. After 128.6 patient-years of follow-up there were 3 deaths unrelated to the procedure, 2 major bleedings (one of them in a patient with an unsuccessful LAAC), thrombus formation over the device in 2 cases (both resolved after resuming OAC for 3 months) and 2 strokes (2.2%). Conclusions: In this multicenter, real world registry, that included patients with NVAF and high thromboembolic and bleeding risks, LAAC effectively prevented stroke and bleeding when compared to the expected rates based on CHA2DS2VASc and HASBLED scores for this population. Complications rate of the procedure was acceptable considering the beginning of the learning curve of most of the involved operators.


Resumo Fundamento: A oclusão percutânea do apêndice atrial esquerdo (OAAE) é uma alternativa eficaz à anticoagulação oral (ACO) para a prevenção de acidente vascular cerebral (AVC) em pacientes com fibrilação atrial não-valvular (FANV). Objetivo: Apresentar os resultados imediatos e o seguimento tardio de pacientes submetidos a OAAE e incluídos no Registro Brasileiro de Oclusão Percutânea do Apêndice Atrial Esquerdo. Métodos: 91 pacientes com FANV, alto risco de AVC (escore CHA2DS2VASc = 4,5 ± 1,5) e restrição à AO (escore HAS-BLED = 3,6 ± 1,0) foram submetidos a 92 procedimentos de OAAE com as próteses Amplatzer Cardiac Plug e Watchman em 11 centros do Brasil, entre o final de 2010 e a metade de 2016. Resultados: Utilizaram-se 96 próteses no total (1,04 próteses/procedimento, incluindo-se o uso de 1 prótese não-dedicada adicional em um dos casos), obtendo-se sucesso em 97,8% dos procedimentos. Realizaram-se procedimentos associados à OAAE em 8,7% dos pacientes. Observou-se oclusão total do AAE em 93,3% dos casos com sucesso, e nos casos de oclusão incompleta, nenhum leak foi > 2,5 mm. Um paciente necessitou do implante simultâneo de 2 próteses. Houve 7 complicações maiores periprocedimento (5 derrames pericárdicos necessitando pericardiocentese, 1 embolização da prótese não-dedicada e 1 embolia aérea coronariana sem sequelas) e 4 menores. No seguimento de 128,6 pacientes-ano, houve 3 óbitos não relacionados ao procedimento, 2 sangramentos maiores (um deles em um dos casos de insucesso da OAAE), formação de trombo sobre a prótese em 2 casos (tratados com sucesso com reinstituição da ACO por 3 meses), e 2 AVCs (2,2%). Conclusões: Neste registro multicêntrico de mundo real, que incluiu pacientes com FANV e alto risco de sangramento e de eventos tromboembólicos, a OAAE foi eficaz na prevenção de AVC e sangramento quando comparada às taxas de AVC previstas pelos escores CHA2DS2VASc e HASBLED para esta população. O índice de complicações do procedimento foi aceitável, considerando se tratar do início da curva de aprendizado da maioria dos operadores envolvidos.


Subject(s)
Humans , Male , Female , Aged , Atrial Fibrillation/surgery , Atrial Appendage/surgery , Stroke/prevention & control , Septal Occluder Device , Atrial Fibrillation/diagnostic imaging , Follow-Up Studies , Treatment Outcome , Echocardiography, Transesophageal , Atrial Appendage/diagnostic imaging , Stroke/etiology
4.
Arq. bras. cardiol ; 101(5): 379-387, nov. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-696881

ABSTRACT

FUNDAMENTO: Na angioplastia coronária percutânea (ACP), os vasos de fino calibre representam um fator de risco para reestenose. O stent farmacológico (SF) autoexpansível Sparrow®, de perfil menor que os sistemas atuais, nunca foi testado nesse cenário. OBJETIVOS: Avaliar a eficácia tardia do SF Sparrow®, com relação à perda luminal tardia intrastent (PLT intrastent) aos oito meses. MÉTODOS: Estudo prospectivo, randomizado, em P com doença arterial coronária (DAC) sintomática ou com isquemia documentada, submetido à ACP em vasos de calibre < 2,75 mm, dividido em dois grupos quanto ao tipo de stent Sparrow®: grupo 1, SF; grupo 2, stent não farmacológico (SNF). O seguimento clínico foi de 12 meses. De imediato e aos oito meses, avaliação pela angiografia coronária quantitativa (ACQ). Para o cálculo da amostra estimou-se diminuição de mais de 65% de PLT intrastent com o SF. Para análise estatística utilizou-se o programa IBM SPSS Statistics® versão 19 (Chicago, Illinois, EUA). RESULTADOS: Foram incluídos 24 p, 12 em cada grupo. Os grupos SF e SNF foram semelhantes quanto à idade (63,25 ± 10,01 versus 64,58 ± 11,54, p = 0,765), sexo masculino (58,3% versus 33,3%, p = 0,412), fatores de risco e todos os aspectos angiográficos. Os resultados imediatos foram satisfatórios em ambos os grupos. Aos oito meses, a PLT intrastent foi significativamente menor no SF do que no SNF (SF 0,25 ± 0,16 versus SNF 0,97 ± 0,76, p = 0,008). CONCLUSÃO: Em ACP de vasos de calibre < 2,75 mm, o SF Sparrow® determinou significativa redução da PLT intrastent, em comparação ao SNF Sparrow®.


BACKGROUND: Small vessels represent a risk factor for restenosis in percutaneous coronary angioplasty (PCA). The Sparrow® self-expanding drug-eluting stent, which has a lower profile than the current systems, has never been tested in this scenario. OBJECTIVES: To evaluate the late effectiveness of the Sparrow® drug-eluting stent, regarding in-stent late lumen loss (LLL). METHODS: Patients with ischemia, symptomatic or documented, were submitted to PCA in vessels with reference diameter < 2.75 mm, divided into two groups regarding Sparrow® stent type: group 1: Sparrow® drug-eluting stent (DES), group 2: Sparrow® bare metal stent (BMS). Clinical follow-up duration was 12 months. Evaluation using quantitative coronary angiography (QCA) was performed immediately and at 8 months. A decrease of over 65% of in-stent LLL with DES was estimated to calculate sample size. IBM® SPSS software, release 19 (Chicago, Illinois, USA) was used for the statistical analysis. RESULTS: A total of 24 patients were randomized, 12 in each group. The DES and BMS groups were similar in age (63.25 ± 10.01 vs. 64.58 ± 11.54, p = 0.765), male gender (58.3% vs. 33.3%, p = 0.412), risk factors and all angiographs aspects. Immediate results were satisfactory in both groups. At 8 months in-stent late lumen loss was significantly lower in DES than in BMS group (DES vs. BMS 0.25 ± 0.16 0.97 ± 0.76, p = 0.008). CONCLUSION: In small-vessel PCA, the Sparrow® DES determined significant reduction in in-stent LLL, when compared to Sparrow® BMS.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Coronary Restenosis/prevention & control , Coronary Vessels/physiopathology , Drug-Eluting Stents , Miniaturization , Angioplasty, Balloon, Coronary , Coronary Stenosis , Stents , Sirolimus/administration & dosage , Treatment Outcome
5.
Radiol. bras ; 44(2): 90-96, mar.-abr. 2011. ilus, tab
Article in Portuguese | LILACS | ID: lil-588194

ABSTRACT

OBJETIVO: Este trabalho teve como objetivo estimar os valores de doses de radiação recebidas por médicos e pacientes em procedimentos intervencionistas cardíacos realizados em um hospital público na cidade de Recife, Pernambuco. MATERIAIS E MÉTODOS: As medidas foram determinadas em 31 pacientes adultos, dos quais 22 tiveram acompanhamento clínico após o procedimento, e em dois cardiologistas com mais de dez anos de experiência. Parâmetros de irradiação para cada procedimento foram registrados. RESULTADOS: Os valores obtidos para a dose absorvida máxima na pele do paciente variaram entre 612 e 8.642 mGy, sendo que 53 por cento foram maiores que 2.000 mGy, valores estes que podem causar efeitos determinísticos. Com relação aos médicos, a dose efetiva média por procedimento foi de 11 µSv e os valores médios do equivalente de dose nas extremidades, mais altos, foram: 923 µSv no pé esquerdo, 514 µSv no pé direito, 382 µSv na mão esquerda e 150 µSv no olho esquerdo. Dependendo do número de procedimentos, as doses recebidas pelos médicos podem exceder os valores limites de doses estabelecidos pelas normas nacionais e internacionais. CONCLUSÃO: Os resultados obtidos sinalizam a necessidade de adoção de estratégias para otimização da proteção radiológica tanto de pacientes quanto de médicos.


OBJECTIVE: The present study was aimed at estimating the values of radiation doses received by physicians and patients during interventional cardiology procedures performed at a public hospital in the city of Recife, Pernambuco, Brazil. MATERIALS AND METHODS: Measurements were made in two cardiologists with more than ten years of experience and in 31 adult patients, with 22 of them being clinically followed-up after the procedure. The individual irradiation parameters were documented. RESULTS: The values for maximum patients skin dose ranged between 612 and 8,642 mGy, achieving more than 2,000 mGy in 53 percent of the patients; such dose values may cause deterministic effects. As regards the physicians, the mean effective dose per procedure was 11 µSv, and the highest mean equivalent doses in the limbs were 923 µSv in the left foot, 514 µSv in the right foot, 382 µSv in the left hand, and 150 µSv in the left eye. Depending on the number of procedures, the doses received by the physician may exceed the dose limits established by the Brazilian and international standards. CONCLUSION: The obtained results indicate the necessity of adopting strategies for optimizing the radiological protection for both patients and physicians.

SELECTION OF CITATIONS
SEARCH DETAIL